Ampligen for Chronic Fatigue Syndrome: Another Delay From the FDA

NEWSBRIEF: The FDA's May 25 deadline has passed, and once again we don't have a decision on Ampligen (poly I: poly C12U), which is vying to become the first approved treatment for chronic fatigue syndrome. According to Ampligen's manufacturer, Hemispherx Biopharma Inc., the FDA says it will need another 1-2 weeks because of "staff scheduling changes."

In other Ampligen-related news, Japanese researchers are now looking at whether this drug is effective against swine flu (H1N1).